Literature DB >> 10428205

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

J F Carew1, D A Kooby, M W Halterman, H J Federoff, Y Fong.   

Abstract

This study evaluates inhibition of human squamous cell carcinomas (SCCs) by a replication-competent multimutated herpes simplex virus type 1 (G207). Infectivity and cytotoxicity of the G207 virus were evaluated in vitro in seven human SCC cell lines. In vivo effects of the G207 virus on human tumor xenografts in an athymic rat model were then investigated by injecting established tumors with 1 x 10(7) virus particles and monitoring tumor growth. In addition, oral cavity tumors in immunocompetent hamster were infected with the G207 virus by selective intraarterial perfusion and the tumor response was monitored. In vitro studies demonstrated infection rates, measured 24 hr after exposure, exceeding 40% at an MOI of 2 in five of seven human SCC cell lines. Cytotoxic effects, as measured by percent cell death on day 5, exceeded 90% in five of seven SCC cell lines. In vivo inhibition of tumor growth in an athymic rat model was seen (p < 0.005) and in two of the cell lines a complete clinical response was seen in 12 of 14 tumors. In the hamster model, selective intraarterial perfusion with G207 virus showed selective infection of the tumor cells, with sparing of the adjacent normal mucosa, which leading to significant suppression of tumor growth (p < 0.005). The G207 virus displayed efficient and selective cytotoxicity and tumor growth inhibition against human SCC and may prove useful as a therapeutic agent for head and neck SCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428205     DOI: 10.1089/10430349950017608

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

1.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

2.  Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.

Authors:  Tae-Jin Song; David P Eisenberg; Prasad S Adusumilli; Michael Hezel; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

3.  Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus.

Authors:  Michael Mullerad; David P Eisenberg; Timothy J Akhurst; Prasad S Adusumilli; Christopher C Riedl; Amit Bhargava; Mithat Gonen; Ronald Finn; Peter T Scardino; Yuman Fong
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

4.  Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.

Authors:  Brendon M Stiles; Prasad S Adusumilli; Stephen F Stanziale; David P Eisenberg; Amit Bhargava; Teresa H Kim; Mei-Ki Chan; Rumana Huq; Mithat Gonen; Yuman Fong
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

5.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

6.  Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

Authors:  Sandeep Malhotra; Teresa Kim; Jonathan Zager; Joseph Bennett; Michael Ebright; Michael D'Angelica; Yuman Fong
Journal:  Surgery       Date:  2007-02-14       Impact factor: 3.982

Review 7.  Regional liver therapy using oncolytic virus to target hepatic colorectal metastases.

Authors:  Susanne G Carpenter; Joshua Carson; Yuman Fong
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

8.  Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer.

Authors:  S Okunaga; A Takasu; N Meshii; T Imai; M Hamada; S Iwai; Y Yura
Journal:  Cancer Gene Ther       Date:  2015-02-06       Impact factor: 5.987

9.  A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.

Authors:  Yuman Fong; Teresa Kim; Amit Bhargava; Larry Schwartz; Karen Brown; Lynn Brody; Anne Covey; Matthias Karrasch; George Getrajdman; Axel Mescheder; William Jarnagin; Nancy Kemeny
Journal:  Mol Ther       Date:  2008-11-18       Impact factor: 11.454

10.  Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.

Authors:  Prasad S Adusumilli; Brendon M Stiles; Mei-Ki Chan; Michael Mullerad; David P Eisenberg; Leah Ben-Porat; Rumana Huq; Valerie W Rusch; Yuman Fong
Journal:  J Gene Med       Date:  2006-05       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.